Stock Price Quote

SEQUENT SCIENTIFIC LTD.

NSE : SEQUENTBSE : 512529ISIN CODE : INE807F01027Industry : Pharmaceuticals & DrugsHouse : Sequent
BSE199.65-8 (-3.85 %)
PREV CLOSE ( ) 207.65
OPEN PRICE ( ) 207.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 160420
TODAY'S LOW / HIGH ( )198.00 207.70
52 WK LOW / HIGH ( )111 260.3
NSE199.70-7.73 (-3.73 %)
PREV CLOSE( ) 207.43
OPEN PRICE ( ) 207.43
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 199.70 (370)
VOLUME 2136594
TODAY'S LOW / HIGH( ) 197.75 207.44
52 WK LOW / HIGH ( )117.35 257.85
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-06 1985
Management Info
Kamal K Sharma - Chairman Rajaram Narayanan - Managing Director
Registered Office

Address 3rd Floor, Srivalli’s Corporate,Plot No. 290, S Y N 33 34 P To 39,Guttala Begumpet, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 9391139986

Email investorrelations@sequent.in

Website www.sequent.in

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

19Nov Sequent Scientific informs about updates
Sequent Scientific has informed that in furtherance of the previous disc..
17Nov Sequent Scientific informs about inves
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
11Nov Sequent Scientific informs about confe
Sequent Scientific has informed that the Company has scheduled a confere..
11Aug Sequent Scientific informs about confe
Sequent Scientific has informed that the audio recording of the earnings..
16Jul Sequent Scientific informs about newsp
Pursuant to Regulation 30 the Securities and Exchange Board of India (Li..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit30.8158
Gross Profit 43.4 220.5
Operating Profit 91.1395.6
Net Sales 340.31782.6

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE)
peergroup  5689.30 (1.38%)
M.Cap ( in Cr)68024.12
Abbott India (BSE)
peergroup  28869.35 (0.15%)
M.Cap ( in Cr)61345.35
Glaxosmithkline Phar (BSE)
peergroup  2543.10 (1.35%)
M.Cap ( in Cr)43081.65
Wockhardt (BSE)
peergroup  1360.10 (2.16%)
M.Cap ( in Cr)22100.56
RPG Life Sciences (BSE)
peergroup  2228.80 (1.27%)
M.Cap ( in Cr)3686.22

Shareholding Pattern

PROMOTERS 52.33%
NON-INSTITUTION 28.85%
MUTUAL FUNDS/UTI 10.04%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Sequent Scientific Ltd.

Sequent Scientific Ltd. was incorporated in the year 1985. Its today's share price is 199.65. Its current market capitalisation stands at Rs 5050.13 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1823.57 Cr and Total Income of Rs.2291.94 Cr. The company's management includes Revati Kasture, Rajaram Narayanan, Gregory John Andrews, Fabian Kausche, Hari Babu Bodepudi, Milind Sarwate, Kamal K Sharma, Yoshita Vora.

It is listed on the BSE with a BSE Code of 512529 , NSE with an NSE Symbol of SEQUENT and ISIN of INE807F01027. It's Registered office is at 3rd Floor, Srivalli’s Corporate,Plot No. 290, S Y N 33 34 P To 39,Guttala Begumpet, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.